Aradigm To Host Key Opinion Leader Breakfast For Non-Cystic Fibrosis Bronchiectasis On April 23 In NYC

Aradigm To Host Key Opinion Leader Breakfast For Non-Cystic Fibrosis Bronchiectasis On April 23 In NYC

Aradigm Corporation recently announced that it will be hosting a Key Opinion Leader Breakfast for Non-Cystic Fibrosis Bronchiectasis in New York on Thursday, April 23, 2015 between 8:00 and 9:30 am. The event will feature a presentation from David Griffith, MD.

Dr. Griffith is a Professor of Medicine, Director of the Center for Pulmonary Infectious Disease Control and the Division Chief of the Pulmonary and Critical Care at the University of Texas Health Science Center at Tyler (UTHSCT). Griffith has held the William A. and Elizabeth B. Moncrief Distinguished Professorship Chair at UTHSCT since 2002, and he is the Chief of the Medical Staff at the Texas Center for Infectious Disease (TCID) in San Antonio, and the Assistant Medical Director of the San Antonio-based Heartland National Tuberculosis Center. He is recognized worldwide as an expert in Bronchiectasis.

Dr. Griffith’s current research interests are the treatment and epidemiology of nontuberculous mycobacteria (NTM) diseases, and treatment and pathogenesis of bronchiectasis. Bronchiectasis is a common co-morbidity that occurs in pulmonary NTM infections. He is co-author and author on more than 180 publications such as peer reviewed articles, book chapters, editorials, reviews and electronic publications. His main areas of interest have been the study of mycobacterial diseases, with an emphasis on NTM diseases in patients with bronchiectasis. He led several research projects and clinical trials that led to new treatment standards for these patients. Griffith was the principal author for the latest American Thoracic Society and Infectious Diseases Society of America Guidelines for the Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases.

A corporate overview will be provided by Aradigm’s executive management team and it will be included an update concerning Pulmaquin®, the investigational drug which is an Aradigm’s proprietary inhaled antibiotic product candidate that is now in two Phase 3 clinical trials in non-CF BE patients.

Read More Recent News Concerning Pulmaquin

Aradigm Corporation was also recently granted a new composition of matter patent regarding its formulations of liposomal and free ciprofloxacin from both the European Patent Office and the Austrian authorities. The patent granted within the countries of the European Union and Australia protect the company’s lead investigational product Pulmaquin for the treatment of lung diseases, such as non-cystic fibrosis bronchiectasis.